

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 28th January, 2020

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id : 506365

Subject : SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Quarter ended 31st December, 2019 as under -


1.	Regulation 33	Un-audited Quarterly for the Quarter ended 31/12/2019 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 28/01/2020

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)



Place: Mumbai
Encl: as above



LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **31st December, 2019**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s VMD & Co.
Chartered Accountants
FRN: 125002W

CA Amit Ganpule
Partner
MRN: 114222



Dated: January 7, 2020
Place: Mumbai
UDIN: 20114222AAAAAH6837

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG, SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
 Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DECEMBER 2019

Sr. No.	Particulars	(Rupees in Thousand)					
		Quarter Ended			Nine Months Ended		Year Ended
		31st Dec., 2019	30th Sept 2019	31st Dec., 2018	31st Dec., 2019	31st Dec., 2018	31st March 2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations						-
II	Other Income	1,499	2,779	1,420	7,109	3,959	8,225
III	Total Revenue (I + II)	1,499	2,779	1,420	7,109	3,959	8,225
IV	Expenses						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	574	430	624	1,409	1,692	2,218
	(5) Depreciation and Amortisation Expenses	-	-	-	-	-	47
	(6) Administrative and Other Expenses	242	564	284	1,740	1,497	3,414
	i) Professional Charges	-	-	125	-	420	-
	ii) Annual Listing Fees	-	-	-	-	310	-
	iii) Share Registry Expenses	-	-	269	-	347	-
	iv) Postal Charges	-	-	-	-	57	-
	(7) Finance Costs	-	-	-	-	-	-
	Total Expenses	816	994	1,302	3,149	4,323	5,679
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	683	1,785	118	3,960	(364)	2,546
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	683	1,785	118	3,960	(364)	2,546
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	683	1,785	118	3,960	(364)	2,546
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	460
	(2) Tax Adjustment Previous Year	-	-	-	-	-	23
	(3) Deferred Tax	-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	683	1,785	118	3,960	(364)	2,063
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	683	1,785	118	3,960	(364)	2,063
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	683	1,785	118	3,960	(364)	2,063
XVIII	Earnings per Share :						
	(1) Basic	0.46	1.19	0.08	2.64	(0.24)	1.38
	(2) Diluted						

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Nine Months Ended 31.12.2019 have been reviewed by the Audit Committee in their Meeting held on 28.01.2020 and approved by the Board of Directors of its Meeting held on 28.01.2020. The Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place : Mumbai

Date : 28th January, 2020



Ashok Somani

Ashok Somani
Director

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG, SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2019

(Rs. In Thousand)

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			NINE MONTHS ENDED		AUDITED YEAR ENDED
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)	683.00	1,785.00	118.00	3,960.00	(364.00)	2,063
Benefit / (Charge):	-	-	-	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	-	-	-	-	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-
Net Profit / (Loss) for the Period (as per AS)	683.00	1,785.00	118.00	3,960.00	(364.00)	2,063



Ashok Somani
Ashok Somani
Director

Mumbai, 28th January, 2020